Education
About Us
Working with TipRanks
Follow Us
Vectus Biosystems Limited (AU:VBS)
ASX:VBS
VBS Stock Chart & Stats
AU$0.18
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.18
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.04 - AU$0.46
Previous CloseN/A
Volume32.26K
Average Volume (3M)97.35K
Market Cap
AU$8.28M
Enterprise ValueAU$8.23M
Total Cash (Recent Filing)AU$250.99K
Total Debt (Recent Filing)AU$200.00K
Price to Earnings (P/E)―
Beta0.07
Next Earnings
Feb 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding53,433,330
10 Day Avg. Volume169,215
30 Day Avg. Volume97,349
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-8.29
Price to Sales (P/S)4.45
P/FCF Ratio-2.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross Profit MarginA high gross profit margin indicates the company retains substantial revenue after direct costs, a durable advantage for biotech businesses. If management can control operating expenses, this margin provides structural capacity to scale R&D or commercialization and improve operating leverage over months.
Improving EPS TrendA positive EPS growth rate suggests per-share profitability metrics have improved versus prior periods. Over a 2–6 month horizon, sustained EPS improvement can reflect rising operational efficiency or margin recovery, supporting long-term ability to reinvest, reduce losses, and attract capital if the trend continues.
Biotech Industry ExposureOperating in biotechnology provides structural demand for innovation, long product lifecycles, and potential for IP-driven competitive advantages. This industry exposure affords durable opportunities for value creation through successful R&D, licensing, or partnerships that can materially change fundamentals over months to years.
Bears Say
Sharp Revenue ContractionA near‑46% revenue decline is a material, persistent deterioration in top-line scale. Loss of revenue reduces fixed cost absorption, undermines margins, and limits the firm's ability to fund R&D or commercialization. Absent a structural revenue recovery plan, this trend threatens medium‑term viability.
Negative Operating And Free Cash FlowSustained negative operating and free cash flows indicate the business cannot generate internal liquidity to fund operations or investment. Over several months this forces reliance on external financing or asset sales, raises dilution or solvency risk, and constrains strategic options and growth execution.
Negative Shareholders' EquityNegative stockholders' equity signals balance sheet distress and potential insolvency risk. This structural weakness limits access to debt and equity markets, increases borrowing costs, and reduces resilience to shocks, impairing the company's capacity to support R&D, commercial launches, or recover from revenue setbacks.
Vectus Biosystems Limited News
VBS FAQ
What was Vectus Biosystems Limited’s price range in the past 12 months?
Vectus Biosystems Limited lowest share price was AU$0.04 and its highest was AU$0.46 in the past 12 months.
What is Vectus Biosystems Limited’s market cap?
Vectus Biosystems Limited’s market cap is AU$8.28M.
When is Vectus Biosystems Limited’s upcoming earnings report date?
Vectus Biosystems Limited’s upcoming earnings report date is Feb 20, 2026 which is in 2 days.
How were Vectus Biosystems Limited’s earnings last quarter?
Vectus Biosystems Limited released its earnings results on Aug 29, 2025. The company reported -AU$0.013 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.013.
Is Vectus Biosystems Limited overvalued?
According to Wall Street analysts Vectus Biosystems Limited’s price is currently Overvalued.
Does Vectus Biosystems Limited pay dividends?
Vectus Biosystems Limited does not currently pay dividends.
What is Vectus Biosystems Limited’s EPS estimate?
Vectus Biosystems Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vectus Biosystems Limited have?
Vectus Biosystems Limited has 53,433,330 shares outstanding.
What happened to Vectus Biosystems Limited’s price movement after its last earnings report?
Vectus Biosystems Limited reported an EPS of -AU$0.013 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Vectus Biosystems Limited?
Currently, no hedge funds are holding shares in AU:VBS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vectus Biosystems Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
143.75%
12-Months-Change
Fundamentals
Return on Equity
-289.05%
Trailing 12-Months
Asset Growth
-61.36%
Trailing 12-Months
Company Description
Vectus Biosystems Limited
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for fibrosis and high blood pressure, which include treatments for heart, kidney, liver, and lung diseases. Its lead compound is VB0004, which is aimed at treating the loss of functional tissue to fibrosis, scarring, and high blood pressure. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases. In addition, it develops AccuCal and RealCount software that enhance speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. The company was incorporated in 2005 and is based in Rosebery, Australia.